bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.02.02.703356

Embarrassingly_FASTA: Enabling Recomputable, Population-Scale Pangenomics by Reducing Commercial Genome Processing Costs from $100 to less than $1

Abstract

Computational preprocessing has become the dominant bottleneck in genomics, frequently exceeding sequencing costs and constraining population-scale analysis, even as large repositories grow from tens of petabytes toward exabyte-scale storage to support World Genome Models. Legacy CPU-based workflows require many hours to days per 30x human genome, driving many repositories to distribute aligned or derived intermediates such as BAM and VCF files rather than raw FASTQ data. These intermediates embed reference- and model-dependent assumptions that limit reproducibility and impede reanalysis as reference genomes, including pangenomes, continue to evolve. Although recent work has established that GPUs can dramatically accelerate genomic pipelines, enabling large-cohort processing to shrink from years to days given sufficient parallelism, such workflows remain cost-prohibitive. Here, we introduce Embarrassingly_FASTA, a GPU-accelerated preprocessing pipeline built on NVIDIA Parabricks that fundamentally changes the economics of genomic data management. By rendering intermediate files transient rather than archival, Embarrassingly_FASTA enables retention of raw FASTQ data and reliable use of highly discounted ephemeral cloud infrastructure such as spot instances, reducing compute spend from [~]$17/genome (CPU on-demand) to <$1/genome (GPU spot), and commercial secondary-analysis pricing from [~]$120/genome to compute spend under $1/genome. We demonstrate the impact of this efficiency using a simulated large-cohort pangenome build-up (using variant-union accumulation as a proxy for diversity growth) in Caenorhabditis elegans and humans, highlighting the long tail of unsampled human genetic diversity. Beyond GPU kernels, Embarrassingly_FASTA contributes a transient-intermediate lifecycle and spot-friendly orchestration that makes FASTQ retention and routine recomputation economically viable. Embarrassingly_FASTA thus provides enabling infrastructure for recomputable, population-scale pangenomics and next-generation genomic models. Non-Expert DescriptionReading a persons complete DNA sequence has become fast and inexpensive, but turning that raw data into something scientists can analyze is now one of the biggest obstacles in modern genetics. Today, processing a single genome can take many hours or even days, which makes it difficult and expensive to study large populations or reanalyze data when better methods become available. As a result, many databases store only partially processed DNA instead of the original data, limiting future discoveries. In this work, we present a new system that dramatically speeds up this processing step using graphics processing units (GPUs), the same type of hardware used in modern artificial intelligence. With our approach, a human genome can be processed in about 35 minutes instead of more than 15 hours, and at a fraction of the cost. This makes it practical to keep the original DNA data and reprocess it whenever new tools or reference genomes become available, rather than being locked into outdated results. We also show that this speed and affordability allow researchers to explore genetic diversity at an unprecedented scale. By analyzing both human genomes and those of a small worm species commonly used in research, we demonstrate how new genetic variations continue to emerge as more individuals are studied, especially in humans, where much diversity remains unexplored. Overall, our work helps remove a major barrier to studying DNA at population scale and lays the foundation for future genetic models that could better explain disease, evolution, and human health. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/703356v2_ufig1.gif" ALT="Figure 1"> View larger version (69K): org.highwire.dtl.DTLVardef@11b8fc3org.highwire.dtl.DTLVardef@7b8b60org.highwire.dtl.DTLVardef@fb5a3borg.highwire.dtl.DTLVardef@1e11276_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Walsh, D. J., Njie, e. G.. 2026-02-04. Embarrassingly_FASTA: Enabling Recomputable, Population-Scale Pangenomics by Reducing Commercial Genome Processing Costs from $100 to less than $1. https://doi.org/10.64898/2026.02.02.703356

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

AF3 Inspector: In-Browser 3D Model Visualization and Confidence Analytics for AlphaFold 3

AlphaFold 3 (AF3) has broadened the computational structural biology landscape by predicting all-atom complexes across proteins, nucleic acids, small-molecule ligands, and ions, including chemical modifications. For non-experts, Google provides a fully web-based service to utilize AlphaFold 3. Unfortunately, despite a flexible and rich interface for inputs, the server's outputs are incomplete and complicated for many users, as witnessed hands-on. Not all confidence metrics are displayed, and those that are shown do not present much interactivity; besides, only model number 1 is shown among the 5 produced by the software, and upon download the user finds the models are provided only in CIF format, which is not yet well-known especially among highly practical users. Here, we present the AlphaFold 3 Multi-Model Inspector (AF3 Inspector, https://pdbms.altervista.org/af3viewer/afviewer8.html), an open, client-side, zero-install web application designed to dissect, align, and interactively explore the complete ensemble of structural models produced by AlphaFold 3. Part of the PDB Manipulation Suite (https://pdbms.altervista.org/), the AF3 Inspector operates entirely within web browsers, meaning it is available out of the box in all devices and operating systems. AF3 Inspector delivers 3D visualization in various styles and colors for all models, overlay with backbone alignment if requested, interactive plots for pLDDT profiles, pAE matrices and contact maps, chain-pair interaction heatmaps, automated detection of ligands, ions and post-translational modifications, and rapid mmCIF-to-PDB conversion allowing users to download the more familiar files. The platform addresses critical practical considerations highlighted in recent community benchmarks, such as CASP16, and extends the lightweight, client-side biophysical toolkit paradigm established by the PDB Manipulation Suite (PDBMS).

bioinformatics↗

PanVasc Research for AI assisted evidence analysis in panvascular intervention

Panvascular intervention research requires evidence workflows that preserve source identity, outcome definitions and observation windows. We developed PanVasc Research, an executable research framework, and evaluated a fixed local Qwen3-4B model using two complementary tasks. Fifty ClinicalTrials.gov records from five vascular query strata generated 200 source-fidelity tests with intact evidence or controlled removal of the requested source, primary outcome or timeframe, plus 50 clean controls. A separate 100-statement sample from the official NLI4CT test set assessed clinical-trial entailment and evidence selection against existing expert labels. Generic and checklist prompts used identical evidence and maximum generation budgets; each output was also evaluated with an input-only deterministic contract. Registry exact accuracy was 51/200 (25.5%) with the generic prompt and 77/200 (38.5%) with the checklist; intact-case agreement was 50/50 and 48/50. The rule baseline recovered 200/200 tuples. NLI label accuracy was 48/100 (48.0%) and 50/100 (50.0%), respectively. The source contract retained 35 and 31 incorrect NLI labels in the two arms. Registry references establish fidelity to a registration snapshot, while NLI4CT concerns breast-cancer trials and does not validate vascular expertise. The framework also retains provenance-recorded literature retrieval, structured research planning and local numerical analysis. These experiments support a bounded assessment of source handling and semantic failure, rather than a new foundation model or autonomous scientific discovery. A proposed endpoint representation identifies the additional domain annotation and independent validation required for a panvascular research model.

bioinformatics↗

BiomiX 3.0: A user-friendly platform for democratized multi-omics integration with graph-based learning.

Background Multi-omics integration has emerged as a powerful strategy to decode the molecular complexity of biological systems. However, the diversity of available methods, each designed with distinct assumptions, objectives, and computational requirements, makes method selection, usage and interpretation challenging for nonexpert users. Here we present BiomiX 3.0, an updated version of the BiomiX platform that extends its integration capabilities with four additional methods: Similarity Network Fusion (SNF), NEighborhood-based Multi-Omics clustering (NEMO), Data Integration Analysis for Biomarker discovery using Latent variable approaches for Omics studies (DIABLO), and PRAMIGO (Phenotyping netwoRk Application for Multi-omics InteGratiOn), a novel supervised heterogeneous graph transformer (HGT) introduced in this work. Results We benchmarked all five methods, MOFA, DIABLO, SNF, NEMO, and PRAMIGO, on two independent multiomics datasets derived from a Chronic Lymphocytic Leukemia (CLL) cohort comparing IGHV-mutated and unmutated patients, and a pulmonary tuberculosis (PTB) cohort versus healthy controls. Supervised methods (DIABLO, PRAMIGO) consistently achieved higher condition-specific discrimination as measured by the Adjusted Rand Index (ARI) and the Adjusted Mutual Information (AMI). In contrast, unsupervised methods (SNF, NEMO) revealed alternative patient stratifications driven by independent sources of biological variance while MOFA performed in a semi-supervised way occupies an intermediate position, capturing latent factors that explain both disease-associated and orthogonal sources of variance. Systematic gene-centric analysis of the top-ranked features prioritized by each method was supported by manual biological annotation of shared and method-specific signals. Across cohorts, we annotated 154 shared features (116 genes, 38 metabolites) and 60 method-unique features per cohort, demonstrating that no single integration strategy captures the full landscape of biologically relevant signals. In the CLL cohort, shared features spanned B-cell receptor biology, innate immune signaling, RAS/MAPK activation, and epigenetic regulation, while methodunique features revealed supervised-method-specific insights into vesicle trafficking (DIABLO), immune checkpoints (MOFA), and ncRNA regulation (PRAMIGO). In the PTB cohort, a convergent interferon/innate immune signature dominated shared features across all methods. Still, method-unique analysis uncovered DIABLO-specific acylcarnitine metabolic reprogramming, MOFA-specific restoration of lysosomal trafficking, and PRAMIGO-specific {gamma}{delta} T-cell and immunoglobulin repertoire diversity. Across both cohorts, SNF and NEMO proved useful for detecting biological and technical sources of variation that were orthogonal to the primary condition of interest. Ultimately, PRAMIGO uniquely enables the construction of heterogeneous graphs modeling cross-modal molecular interactions, uncovering epigenetic co-regulation programs in CLL and multi-omics inflammatory modules in PTB that are difficult to identify using conventional integration approaches. Conclusions BiomiX 3.0 provides a graphical user interface (GUI) multi-method integration environment that democratizes access to state-of-the-art multi-omics analysis. By combining both unsupervised and supervised integration strategies within a unified platform and introducing graph-based learning through PRAMIGO, BiomiX 3.0 enables researchers across disciplines with complementary tools to interrogate the biological sources of variation in their data, without requiring bioinformatics expertise.

bioinformatics↗